SV

Street Verdict

Analyst Scorecard

BIOCON · NSE

Biocon Limited

₹364.4

+0.21% (+₹0.75)

Prev. close

₹363.65

Volume

14,76,514

Delivery %

53.1%

As of

20 Nov 2026

Price history

₹364.4-₹53.1 (-12.72%) · 3M
18 Aug 2026 → 20 Nov 2026
34036038040018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

2 analyst stances · last 90 days · one per analyst

Trackable

2 · 2 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (2)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 11 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Biocon Limited

Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Details

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Shreehas Pradeep Tambe MTech

Headquarters

Bengaluru

Employees

16,447

Website

biocon.com

Key stats

Market cap

₹56,109.45 Cr

P/E ratio (TTM)

101.4

Dividend yield

0.15%

EPS (TTM)

₹3.38

Beta (1Y · daily vs NIFTY 50)

0.64

Beta (5Y · monthly vs NIFTY 50)

0.99

Shares float

81.94 Cr

EPS · quarter ended Jun 2026

₹0.87

Financial Performance

01 · Financials

0 Cr5000 Cr10000 Cr15000 Cr20000 Cr₹0%5%10%15%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

02.557.510₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0112₹-100%0%100%200%30 Jun 2207 Jul 2305 Jul 2404 Jul 2503 Jul 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-200%0%200%400%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr25000 Cr50000 Cr75000 Cr₹0×0.5×1×1.5×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr25000 Cr50000 Cr75000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-20000 Cr0 Cr20000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹7,105.80 Cr₹8,184.00 Cr₹11,174.20 Cr₹14,755.70 Cr₹15,261.70 Cr₹16,927.00 Cr
EBITDA
₹1,919.70 Cr₹2,071.80 Cr₹2,429.20 Cr₹4,068.40 Cr₹4,471.00 Cr₹3,394.90 Cr
₹740.50 Cr₹648.40 Cr₹462.70 Cr₹1,022.50 Cr₹1,013.30 Cr₹385.60 Cr
Diluted EPS
₹6.19₹5.42₹3.87₹8.54₹8.46₹2.82

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹18,490.00 Cr₹20,342.00 Cr₹51,742.00 Cr₹55,753.00 Cr₹58,540.00 Cr₹63,409.00 Cr
₹4,481.10 Cr₹5,146.60 Cr₹18,018.80 Cr₹16,276.70 Cr₹18,362.00 Cr₹15,434.10 Cr
Stockholders' equity
₹7,627.00 Cr₹8,432.00 Cr₹17,867.00 Cr₹19,783.00 Cr₹21,644.00 Cr₹34,031.00 Cr

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,160.00 Cr₹1,177.00 Cr₹1,852.00 Cr₹2,954.00 Cr₹4,061.00 Cr₹1,994.00 Cr
Investing cash flow
₹-3,624.70 Cr₹-1,699.10 Cr₹-14,281.80 Cr₹-1,004.50 Cr₹-234.10 Cr₹-2,082.10 Cr
₹2,564.00 Cr₹242.00 Cr₹13,049.00 Cr₹-2,333.00 Cr₹-1,854.00 Cr₹-924.00 Cr
Capital expenditure
₹-1,746.30 Cr₹-6,226.80 Cr₹-1,726.30 Cr₹-1,931.60 Cr₹-2,343.30 Cr₹-1,911.70 Cr
End cash position
—₹653.70 Cr₹1,294.80 Cr₹919.50 Cr₹2,923.80 Cr₹2,111.50 Cr

End cash position has filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25–Jun 25(2Q)Sep 25Dec 25Jan 26Jan 26Mar 26Jun 26–Jun 26(2Q)
Promoter60.64%60.64%60.64%60.64%60.64%60.64%60.64%60.64%60.64%60.64%60.64%60.64%60.64%60.64%60.64%54.45%54.45%54.45%48.27%44.91%44.91%44.68%
Public38.64%38.71%38.74%38.63%38.74%38.78%38.81%38.87%38.97%39.03%39.05%39.08%39.12%39.14%39.15%45.37%45.41%45.43%51.63%54.99%55.00%55.27%
Employee trusts0.72%0.65%0.63%0.73%0.63%0.58%0.55%0.49%0.39%0.33%0.32%0.28%0.25%0.22%0.21%0.18%0.14%0.12%0.10%0.10%0.09%0.05%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Biocon Limited₹56,109.45 Cr₹344.45101.41.651.1%0.45+11.5%-9.5%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

BIOCON

Biocon Gets US FDA Approval for Pebrilzo Breast Cancer Biosimilar; Shares Rise 0.9%

HDFC Sky · 7 days ago

BIOCON

Biocon stock faces mixed Q2 as profit drops 52 percent

ad-hoc-news.de · 10 days ago